- Home
- CVEO vs MREO Comparison
CVEO vs MREO Comparison
Compare CVEO & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVEO
- MREO
- Stock Information
- Founded
- CVEO 1977
- MREO 2015
- Country
- CVEO United States
- MREO United Kingdom
- Employees
- CVEO N/A
- MREO N/A
- Industry
- CVEO Hotels/Resorts
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- CVEO Consumer Discretionary
- MREO Health Care
- Exchange
- CVEO Nasdaq
- MREO Nasdaq
- Market Cap
- CVEO 284.2M
- MREO 311.8M
- IPO Year
- CVEO N/A
- MREO N/A
- Fundamental
- Price
- CVEO $22.15
- MREO $1.79
- Analyst Decision
- CVEO Strong Buy
- MREO Strong Buy
- Analyst Count
- CVEO 1
- MREO 5
- Target Price
- CVEO $27.00
- MREO $7.40
- AVG Volume (30 Days)
- CVEO 90.3K
- MREO 1.4M
- Earning Date
- CVEO 10-31-2025
- MREO 11-12-2025
- Dividend Yield
- CVEO 2.25%
- MREO N/A
- EPS Growth
- CVEO N/A
- MREO N/A
- EPS
- CVEO N/A
- MREO N/A
- Revenue
- CVEO $628,180,000.00
- MREO $500,000.00
- Revenue This Year
- CVEO N/A
- MREO N/A
- Revenue Next Year
- CVEO $2.62
- MREO $72.16
- P/E Ratio
- CVEO N/A
- MREO N/A
- Revenue Growth
- CVEO N/A
- MREO N/A
- 52 Week Low
- CVEO $18.01
- MREO $1.47
- 52 Week High
- CVEO $27.55
- MREO $4.40
- Technical
- Relative Strength Index (RSI)
- CVEO 48.46
- MREO 40.01
- Support Level
- CVEO $21.15
- MREO $1.72
- Resistance Level
- CVEO $22.33
- MREO $2.15
- Average True Range (ATR)
- CVEO 0.84
- MREO 0.11
- MACD
- CVEO -0.00
- MREO -0.04
- Stochastic Oscillator
- CVEO 49.08
- MREO 20.97
About CVEO Civeo Corporation (Canada)
Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).